Intrusion, Inc. (NASDAQ:INTX) shares jumped 41% on Tuesday following the company’s announcement that it has completed the acquisition of cybersecurity managed security service provider VigilAigent from Tego Cyber, a deal expected to immediately expand revenue and commercial reach.
The Plano, Texas-based cyberattack prevention firm said the acquisition adds approximately $3.5 million in annual recurring revenue (ARR) from multi-year customer contracts.
Abivax SA (NASDAQ:ABVX, EPA:ABVX, FRA:2X10, FRA:2X1) shares surged more than 40% on Tuesday after the French biotech released updated safety data from its late-stage ulcerative colitis program for its investigational drug obefazimod, easing earlier market concerns around reported cancer cases in the study.
The company said the additional analysis showed that observed malignancy rates across its Phase 2 and Phase 3 program were consistent with background rates typically seen in patients with ulcerative colitis.
AeroVironment (NASDAQ:AVAV) shares surged about 15% in early trading following the company’s fiscal fourth-quarter results, as investors reacted to stronger-than-expected revenue and earnings, alongside a sharply higher backlog and upbeat defense demand outlook.
AeroVironment (NASDAQ:AVAV) reported Q4 revenue of $641.6 million, a 133% increase from $275.1 million a year earlier and well above Wall Street expectations of about $558 million.
Shares in Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) climbed 24% to 2.35p after the precision diagnostics company published two-year data showing its kidney disease test was linked to lasting improvements in patient health.
The study of 2,470 patients with type 2 diabetes and early-stage chronic kidney disease was carried out across two US health systems, Mount Sinai in New York and Wake Forest/Atrium Health in North Carolina.